Search PubMed⌕ Search

Biomedical subjects

G Henry

Publications and source records attributed to G Henry.

At least 55 records · Page 3Linked to original sources
PubMed1987

The occurrence, recognition and developmental fate of pseudo-multipronuclear eggs after in-vitro fertilization of human oocytes.

The presence of three or more presumed pronuclei in 27 of 884 (3%) in-vitro fertilized human eggs suggested the occurrence of polyspermic fertilization. Detailed examination by differential interference contrast microscopy indicated that approximately 40% of presumed multipronuclear eggs were normally fertilized but contained a cytoplasmic vacuole(s) (pseudo-pronucleus) of pronuclear dimension and gross morphology. Closely timed observations of presumed multipronuclear eggs revealed that pseudo-pronuclei (PPN) can co-migrate and become juxtaposed with true pronuclei, thus presenting the impression of an aberrant fertilization. Fluorescent probe and electron microscopic analyses demonstrated that PPN are enclosed by a plasma membrane and contain neither DNA nor nucleoli. PPN can develop either in the mature oocyte or the newly fertilized egg. Pseudo-multipronuclear eggs progress through the preimplantation stages in an apparently normal fashion and, as demonstrated by one birth and two ongoing pregnancies, are developmentally viable. Criteria for the unambiguous designation of pseudo-multipronuclear eggs are based on: the absence of normal morphodynamic changes associated with pronuclear development; and the failure of nucleoli to appear during the perisyngamic stage. The findings strongly suggest that pseudo-multipronuclear human eggs may represent a class of morphological variants of normally fertilized and developmentally competent eggs.

Cell Nucleolus↗
PubMed1986

Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment.

Milrinone, a new, nonglycosidic inotropic agent with peripheral vasodilating properties, was given as a single oral 5 mg dose to 7 healthy subjects, 7 patients with moderate renal impairment (CRI I, creatinine clearance 30-63 ml/min) and 7 patients with severe renal impairment had hypertension. The mean urinary recovery of milrinone was 82% in healthy subjects, the renal clearance was 288 ml/min and the plasma half-life (t1/2) was 0.94 h. In CRI the mean plasma t1/2 was prolonged (CRI I 1.78 h, CRI II 3.24 h). There was a significant linear relationship between creatinine clearance and the elimination rate constant, and between creatinine clearance and the renal clearance of milrinone. During the study day there was a tendency to a decrease in supine BP from 1 to 6-8 h after dosing, with the maximal decrease at 2-3 h (healthy subjects 118/71----107/56, CRI 159/95----136/79 mmHg). The same degree of change was seen in standing BP. A slight rise in standing HR was seen from 2-6 h after dosing. Changes in BP and HR are difficult to evaluate since the study was not placebo-controlled. The plasma elimination rate of milrinone was decreased in CRI and dose adjustment may be necessary. Placebo-controlled studies of milrinone in hypertensive patients would be required to validate its possible antihypertensive effect.

Adult↗
PubMed1984

Corticofugal axons in the lateral geniculate nucleus of the cat.

Injections of horseradish peroxidase (HRP) were made into the optic radiations just above the lateral geniculate nucleus of four cats to trace the anterograde filling of corticofugal axons terminating in the perigeniculate and lateral geniculate nuclei. The different types of axons were classified according to axonal diameter and the morphology of the terminal appendages. Judging from their morphological organization we suggest that the corticofugal axons are, in the main, slowly conducting and that they have a restricted terminal distribution which extends, however, to a multiplicity of levels in both perigeniculate and lateral geniculate nuclei. These morphological characteristics may have physiological implications in determining the role of the corticofugal pathway.

Animals↗
PubMed1984

Preimplantation human embryonic development from polypronuclear eggs after in vitro fertilization.

The occurrence of grossly normal-appearing morula stage human embryos (8- to 12-cell) that developed from eggs fertilized in vitro containing three pronuclei is described. Serial section analysis by transmission electron microscopy demonstrated that 25% of the blastomeres were multinucleate, with as many as five deoxyribonucleic acid-containing nuclei (determined by fluorescence microscopy) in a single cell. Light and electron microscopy indicated that normal cortical and zona reactions had taken place. Fine-structural development of the cytoplasm was characteristic of morula stage human embryos. The results suggest the need to determine pronuclear number prior to syngamy and are discussed with respect to the notion that human embryos may have the capacity to develop normally in spite of the presence of abnormal cells.

Blastomeres↗
PubMed1982

Short-term treatment for acute myelogenous leukaemia.

Short-term treatment with doxorubicin, cytarabine, and 6-thioguanine was given to 91 consecutive adults with acute myelogenous leukaemia. Fifty patients received high doses (regimen I) and 41 very high doses (regimen II). Where possible, six treatment cycles were given (total dose of doxorubicin 450 mg/m2) regardless of the number of cycles required to achieve complete remission. No additional treatment was given. The remission rate was significantly higher with regimen I than with regimen II (34/50 compared with 15/41, p less than 0.01), the latter, more intensive regimen being associated with a greater incidence of fatal infection (13/41 compared with 5/50, p less than 0.01). Duration of remission was, however, significantly longer with regimen II (p less than 0.05); the median has not yet been reached after a minimum follow-up of two years. Intensive short-term treatment is a feasible strategy for the treatment of acute myelogenous leukaemia.

Adolescent↗
PubMed1979

Spontaneous feminization and menstrual function developing during puberty in Turner's syndrome.

An 18-year-old patient with Turner's syndrome presented with cyclical vaginal bleeding and spontaneous development of secondary sexual characteristics. She demonstrated classic features of Turner's phenotype, and a culture of blood lymphocytes revealed a 45,XO karyotype. The patient's plasma and urinary estrogen concentrations were similar to those in normal adult women in the late proliferative phase. In contrast, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels were elevated to values seen in postmenopausal women. Dynamic testing revealed no estrogen response to human menopausal gonadotropin (/MG) and a paradoxical fall in estrogen after administration of human chorionic gonadotropin (hCG). Administration of luteinizing hormone-releasing hormone (LH-RH) resulted in an exaggerated response of both gonadotropins. Dilatation and curettage revealed endometrial hyperplasia, and a laparotomy revealed the presence of 2 gonadlike structures. The histologic diagnosis was lutein cyst. Karyotyping of lymphocytes, skin from the abdominal incision, and tissue from both gonadal structures revealed a 45,XO karyotype without evidence of mosaicism.

Adolescent↗
PubMed1976

Rh-immune globulin after amniocentesis for genetic diagnosis.

The procedure of amniocentesis during the second trimester of pregnancy for genetic diagnosis creates the potential for Rh sensitization secondary to fetomaternal bleeding. We have advised administration of Rh-immune globulin after such amniocentesis whenever the pregnancy may be Rh-incompatible. Of 56 patients who received Rh-immune globulin there has been only 1 case of Rh sensitization, which occurred in a patient who underwent a second amniocentesis 2 weeks after the first attempt without receiving a second dose of Rh-immune globulin. There have been no developmental problems detected to date which could be ascribed to Rh-immune globulin.

Adult↗